Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Taylor, B. Oppenheim, P. Chadwick, D. Weston, M. Palepou, N. Woodford, M. Bellis (1999)
Detection of glycopeptide-resistant enterococci in routine diagnostic faeces specimens.The Journal of hospital infection, 43 1
D. Ménaché, J. O'Malley (1996)
Creutzfeldt-Jakob disease: current U.S. policy to further reduce the possible risk of transmission by transfusion.Biologicals : journal of the International Association of Biological Standardization, 24 3
F. Houston, J. Foster, A. Chong, N. Hunter, C. Bostock (2000)
Transmission of BSE by blood transfusion in sheepThe Lancet, 356
Ian MacGregor (2001)
Prion protein and developments in its detectionTransfusion Medicine, 11
M. Schmerr, Allen Jenny, Marie Bulgin, Janice Miller, Amirali Hamir, Randall Cutlip, Kathryn Goodwin (1999)
Use of capillary electrophoresis and fluorescent labeled peptides to detect the abnormal prion protein in the blood of animals that are infected with a transmissible spongiform encephalopathy.Journal of chromatography. A, 853 1-2
FROM THE COMMISSION on the precautionary principle
(2001)
Theoretical risk of CJD transmission through blood or blood products – what is known and what is needed? Presented at ‘Prions: Assessment and Management of Risks from Blood-Borne TSE Infectivity
(1999)
Application of a timeresolved fluorimmunoassay for the analysis of normal prion protein in human blood and its components
J. Safar, H. Wille, V. Itri, D. Groth, H. Serban, M. Torchia, F. Cohen, S. Prusiner (1998)
Eight prion strains have PrPSc molecules with different conformationsNature Medicine, 4
Douglas Lee, C. Stenland, Jeanette L.C. Miller, K. Cai, E. Ford, K. Gilligan, R. Hartwell, Jarrett Terry, R. Rubenstein, M. Fournel, Stephen R. Petteway (2001)
A direct relationship between the partitioning of the pathogenic prion protein and transmissible spongiform encephalopathy infectivity during the purification of plasma proteinsTransfusion, 41
M. Scott, R. Will, J. Ironside, Hoang-Oanh Nguyen, P. Tremblay, S. DeArmond, S. Prusiner (1999)
Compelling transgenetic evidence for transmission of bovine spongiform encephalopathy prions to humans.Proceedings of the National Academy of Sciences of the United States of America, 96 26
M. Ricketts, N. Cashman, E. Stratton, S. ElSaadany (1997)
Is Creutzfeldt-Jakob disease transmitted in blood?Emerging Infectious Diseases, 3
Change to the Guidance Entitled 'Revised Precautionary Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) by Blood and Blood Products
R. Will, J. Ironside, M. Zeidler, S. Cousens, K. Estibeiro, A. Alpérovitch, S. Poser, M. Pocchiari, A. Hofman, Peter Smith (1996)
A new variant of Creutzfeldt-Jakob disease in the UKThe Lancet, 347
(2001)
Partitioning of Transmissible Spongiform Encephalopathy (TSE) by Plasma or Biotechnology Manufacturing Processes Presented at ‘The policies and science of prions and plasma workshop
S. Prusiner (1998)
Nobel Lecture: PrionsProceedings of the National Academy of Sciences of the United States of America, 95
P. Brown, L. Cervenakova, L. McShane, P. Barber, R. Rubenstein, W. Drohan (1999)
Further studies of blood infectivity in an experimental model of transmissible spongiform encephalopathy, with an explanation of why blood components do not transmit Creutzfeldt‐Jakob disease in humansTransfusion, 39
D. Taylor, K. Fernie, H. Reichl, R. Somerville (2000)
Infectivity in the blood of mice with a BSE-derived agent.The Journal of hospital infection, 46 1
T. Kawashima, H. Furukawa, K. Doh-ura, T. Iwaki (1997)
Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsyThe Lancet, 350
Andrew Hill, Susan Joiner, Jackie Linehan, Melanie Desbruslais, Peter Lantos, John Collinge (2000)
Species-barrier-independent prion replication in apparently resistant species.Proceedings of the National Academy of Sciences of the United States of America, 97 18
(2001)
Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products -Draft Guidance URL
(2001)
Factor VIII SD-35-15: efficacy and safety clinical data with solventdetergent treated and 35–15 nm filtered factor VIII concentrate
K. Wilson, Catherine Code, M. Ricketts (2000)
Risk of acquiring Creutzfeldt-Jakob disease from blood transfusions: systematic review of case-control studiesBMJ : British Medical Journal, 321
P. Brown, L. Cervenakova, H. Diringer (2001)
Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease.The Journal of laboratory and clinical medicine, 137 1
Prusiner Prusiner (1998)
PrionsPNAS, 95
C. Piersall (1970)
Analysis of Crisis Decision-Making
D. Taylor (1999)
Inactivation of prions by physical and chemical means.The Journal of hospital infection, 43 Suppl
(1996)
Report of the Krever Commission of Inquiry into the Blood System in Canada
The demonstration of iatrogenic transmission of Creuzfeldt–Jakob disease (CJD) through therapeutic interventions led to substantial concerns in communities requiring blood products in the 1980s and 1990s. These concerns led some regulatory authorities to adopt a very precautionary approach and require recall of plasma products, including factor concentrates, which included donors at risk of CJD. The FDA's approach on recall contributed to a substantial lack of plasma products on the world market in the mid‐ to late 1990s. Growing epidemiological evidence of non‐transmission of CJD to humans through blood, as well as demonstration of the plasma fractionation system's ability to eliminate CJD‐type agents, led the FDA to rescind its measures for product recall in 1998. Although no evidence exists that the variant strain of CJD (vCJD) will behave any differently to the classic strain (cCJD) of the disease during fractionation, indications that higher levels of the strain may be present in the blood in vCJD, as well as the uncertainty regarding the epidemiology of the disease, has led to a new round of precautionary measures aimed at minimizing vCJD risk. Currently, the traditional approach to product safety through appropriate donor selection, screening using laboratory tests and systematic pathogen elimination is not completely possible for addressing the risk of vCJD. The only definite risk factor for vCJD is residence in a country where meat products from cattle with bovine spongiform encephalopathy (BSE) have been consumed; currently this is predominantly the United Kingdom but the appearance of BSE in other European countries has stimulated non‐European regulatory authorities to defer blood donors from most of Europe. There is currently no screening test available for vCJD. Plasma fractionation techniques fortuitously appear to eliminate substantial amounts of vCJD like agents but only one pathogen eliminating technique, nanofiltration, has been proposed for specifically eliminating vCJD‐like agents. Despite the current uncertainty, it is possible to be cautiously optimistic regarding the safety of factor concentrates from the risk of vCJD. An accumulating body of evidence suggests that it is unlikely that the plasma pool from countries with moderate BSE epidemics will contain sufficient levels of vCJD agent to lead to an infective final product. Nevertheless, the development of a blood screening test and more dedicated elimination methods are high priorities for the blood industry as it faces this new threat. The community of blood product users, including people with haemophilia, need to be in a position to make an informed choice regarding the risk of this new agent. Such a choice needs to take into account the alternatives to plasma product therapy such as recombinant concentrates and the risks to product supply ensuing from an excessive reliance on one form of product.
Haemophilia – Wiley
Published: May 1, 2002
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.